Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro‐costing analysis in three Italian hematology centers
Cancer Medicine · 2023-12 · 12 (23) · 21480-21489
DOI: 10.1002/cam4.6699 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 09.11.2023. Verfasst von Lorenzo Pradelli und 11 weiteren Autor:innen. Beteiligte Einrichtung: AdRes HE&OR, Torino, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Multiple Myeloma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Daratumumab is a humanized monoclonal antibody approved for the treatment of adult patients with newly diagnosed or relapsed/refractory multiple myeloma (RRMM). Subcutaneous (SC) formulation proved to be non‐inferior in comparison with intravenous (IV) administration route. This study aimed at assessing the economic and time impact associated with the use of SC versus IV daratumumab in patients with RRMM from the perspective of the hematology center.
Methods
This was a 5‐month multicenter time‐and‐motion cross‐sectional micro‐costing study conducted in three Italian hematology centers among adult patients diagnosed with RRMM with ongoing treatment with IV or SC daratumumab. Measurements were performed by an ad hoc App.
Results
Nineteen (20%) IV and 76 (80%) SC administration procedures were measured. Patients spent a mean of 4.85 ± 0.91 or 1.08 ± 0.56 h in the hematology center to receive IV or SC daratumumab, respectively. Healthcare professionals (HCPs) spent a mean of 49.38 ± 16.13 and 20.37 ± 7.88 min of active working time to manage IV and SC administrations, respectively. The infusion chair was occupied for a mean of 4.85 ± 0.91 and 0.99 ± 0.55 h during IV or SC administration, respectively. On average, considering the costs due to HCP and chair time, materials, and overhead costs, every IV and SC administration costed €80.33 and 34.90, respectively.
Conclusions
In conclusion, as compared with IV administration, SC daratumumab was associated with 78%, 59%, 80% savings in terms of patient time, HCP active working time, and infusion chair, respectively, and 56.6% budget savings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AdRes HE&OR, Torino, Italy.
- S.C. Ematologia A.O. Santa Croce e Carle, Cuneo, Italy.
- U.O. Ematologia ASST Valle Olona Busto Arsizio, Busto Arsizio, Italy.
- Divisione di Ematologia, Ospedale Cà Foncello di Treviso-ASL 2, Treviso, Italy.
- Janssen-Cilag SpA, Cologno Monzese, Italy.
ORCID-Profile: Lorenzo Pradelli, Anna Furlan
Zitieren
APA
Pradelli, L., Massaia, M., Todisco, E., Gherlinzoni, F., Furlan, A., La Targia, M., Grande, E., Tripoli, I. E., Occhipinti, F., Comello, F., Iannello, F., & Bellucci, S. (2023). Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro‐costing analysis in three Italian hematology centers. Cancer Medicine, 12(23), 21480-21489. https://doi.org/10.1002/cam4.6699
Vancouver
Pradelli L, Massaia M, Todisco E, Gherlinzoni F, Furlan A, La Targia M, et al. Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro‐costing analysis in three Italian hematology centers. Cancer Medicine. 2023;12(23):21480-21489. doi:10.1002/cam4.6699
BibTeX
@article{Pradelli2023,
author = {Pradelli, Lorenzo and Massaia, Massimo and Todisco, Elisabetta and Gherlinzoni, Filippo and Furlan, Anna and La Targia, Maria and Grande, Elisabetta and Tripoli, Ignazio Ezio and Occhipinti, Francesca and Comello, Francesco and Iannello, Fabrizio and Bellucci, Stefania},
title = {Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro‐costing analysis in three Italian hematology centers},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {23},
pages = {21480--21489},
doi = {10.1002/cam4.6699}
}
EUVIMED